Proactive Investors - Run By Investors For Investors

Redfund Capital to launch Dr Klein CBD brand

The line of pharma-grade nutraceuticals includes a pain cream and CBD bath bombs
Cannabis leaf and cream
The company plans to initially target the US chiroprac community, of which Klein is a member

Redfund Capital Corp (CSE:LOAN) (FRA:O3X4) (OTC:PNNRF) is launching a line of pharma-grade cannabidiol nutraceuticals headed by Robert Klein.

The Dr. Klein CBD brand includes a pain cream, healing stick, face moisturizer, infused serum and CBD-infused bath bombs.

The company plans to initially target the US chiropractic community, of which Klein is a member, through online consumer marketing before launching globally in the fall.

READ: Redfund Capital to fund Cannamerx cannabis exchange

“We are pleased to support Dr. Klein and the launch of the Dr. Klein CBD brand of pharma-grade CBD topicals and infused bathing products,” CEO Meris Kolt said. “These products will be laboratory tested prior to sales. We look forward to launching the Dr. Klein brand into Europe, South America and into Canada when regulation allows in the fall of 2019.”

Klein has been the chiropractor for Florida Atlantic University for 15 years and serves on the board of the Florida Chiropractic Association. He earned his doctorate from the National College of Chiropractic in Lombard, Illinois.

Redfund Capital provides debt and equity funding to companies in the medical cannabis community. The company will own an equity stake in Dr. Klein CBD.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full LOAN profile View Profile

Redfund Capital Corp. Timeline

Related Articles

medical cannabis
October 31 2018
Redfund Capital continues to expand, with the launch of its subsidiary, First Euro Cannabis
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use